Honda Y, Hosoya M, Ishii T, Shigeta S, Suzuki H
Department of Pediatrics, Fukushima Medical College, Japan.
Antimicrob Agents Chemother. 1994 Apr;38(4):653-5. doi: 10.1128/AAC.38.4.653.
The antiviral activity of ribavirin was studied in hamsters infected with subacute sclerosing panencephalitis (SSPE) virus. Ribavirn did not improve the survival of infected hamsters when administered intraperitoneally at the maximal nonlethal dose of 50 mg/kg/day for 10 days. However, when administered intracranially, ribavirin improved the survival of infected hamsters in a dose-dependent manner. The 50% effective dose was calculated to be 1.4 mg/kg/day, and the selectivity index, based on the ratio of the 50% lethally toxic dose (31 mg/kg/day) to the 50% effective dose, was 22. When begun 12 h, but not 36 h, postinfection, ribavirin at a dose of 10 mg/kg/day completely prevented mortality and inhibited the replication of SSPE virus in brains of infected hamsters. Intrathecal or intraventricular administration of ribavirin should be explored for potential use in the treatment of patients with SSPE.
研究了利巴韦林对感染亚急性硬化性全脑炎（SSPE）病毒的仓鼠的抗病毒活性。当以50毫克/千克/天的最大非致死剂量腹腔注射10天时，利巴韦林并未提高受感染仓鼠的存活率。然而，当颅内给药时，利巴韦林以剂量依赖的方式提高了受感染仓鼠的存活率。计算出50%有效剂量为1.4毫克/千克/天，基于50%致死毒性剂量（31毫克/千克/天）与50%有效剂量之比的选择性指数为22。在感染后12小时而非36小时开始给药时，10毫克/千克/天剂量的利巴韦林完全预防了死亡，并抑制了SSPE病毒在受感染仓鼠脑中的复制。应探索鞘内或脑室内给予利巴韦林在治疗SSPE患者中的潜在用途。
